Mangoceuticals (MGRX) Net Equity Issued and Repurchased (2023 - 2025)

Mangoceuticals (MGRX) has 3 years of Net Equity Issued and Repurchased data on file, last reported at $2.2 million in Q4 2025.

• For the quarter ending Q4 2025, Net Equity Issued and Repurchased rose 191.45% year-over-year to $2.2 million; the trailing twelve-month figure through Dec 2025 stood at $4.6 million (up 248.22% YoY), and the FY2025 full-year result was $4.6 million, up 248.22% from the prior year.
• Net Equity Issued and Repurchased rose to $2.2 million in Q4 2025, from $1.3 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $5.0 million in Q1 2023 to a low of $180000.0 in Q1 2024.
• A 3-year average of $1.3 million and a median of $707499.0 in 2024 frame the typical range for Net Equity Issued and Repurchased.
• Across the five-year window, Net Equity Issued and Repurchased plunged 96.4% in 2024 and surged 263.89% in 2025, its largest moves.
• Tracing MGRX's Net Equity Issued and Repurchased over 3 years: stood at $1.2 million in 2023, then plunged by 36.67% to $759998.0 in 2024, then jumped by 191.45% to $2.2 million in 2025.
• Business Quant data shows MGRX's Net Equity Issued and Repurchased at $2.2 million in Q4 2025, $1.3 million in Q3 2025, and $430785.0 in Q2 2025.